Pathnostics

Pathnostics is a private, commercial-stage diagnostics company specializing in transformative testing for complicated, recurrent, and persistent UTIs through its Guidance® platform. The company's core innovation combines multiplex PCR with Pooled Antibiotic Susceptibility Testing (P-AST™) to identify pathogens and their antibiotic resistance profiles more accurately than standard culture, particularly for polymicrobial infections. Operating from a CAP-accredited, CLIA-certified lab, Pathnostics serves urologists, gastroenterologists, OB/GYNs, and primary care physicians, with a growing portfolio that includes tests for Barrett's Esophagus. It is positioned to address critical needs in antibiotic stewardship and improved patient outcomes in chronic infectious diseases.

Guidance® platform combining multiplex PCR for pathogen detection with proprietary Pooled Antibiotic Susceptibility Testing (P-AST™) to phenotype antibiotic resistance in polymicrobial samples.

Pathnostics competes in the UTI diagnostics space against standard urine culture (the entrenched incumbent) and a growing number of molecular PCR panels from companies like BioFire (BioMérieux), QIAGEN, and SpeeDx. Its primary differentiation is the phenotypic P-AST™ component, which addresses polymicrobial interactions—a gap most PCR-only tests do not fill. In Barrett's Esophagus, it competes with traditional histopathology and other cytology/FISH-based tests.